What it's for (Indications)
- Dorzolamide and timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- This combination medication is particularly useful for patients who are insufficiently responsive to beta-blockers alone or for whom monotherapy with a beta-blocker is inappropriate due to insufficient IOP reduction.
- The synergistic action of dorzolamide (a carbonic anhydrase inhibitor) and timolol (a non-selective beta-adrenergic receptor blocker) provides an enhanced IOP-lowering effect compared to either agent used alone.
- By reducing aqueous humor production, the medication helps to prevent progressive optic nerve damage and subsequent visual field loss associated with chronic elevated IOP, which is characteristic of glaucoma.
- Its use is critical in preserving visual function in affected individuals.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage for dorzolamide and timolol ophthalmic solution is one drop instilled into the conjunctival sac of the affected eye(s) twice daily. This regimen should be administered approximately 12 hours apart to maintain consistent intraocular pressure reduction. Patients should be instructed on proper instillation techniques to minimize systemic absorption and contamination, including pressing on the nasolacrimal duct or closing the eyelid gently for at least one minute after instillation. If more than one topical ophthalmic medication is being used, there should be an interval of at least five minutes between the administration of each medication. Adherence to the prescribed frequency and duration is crucial for optimal therapeutic outcomes and to prevent fluctuations in intraocular pressure, which can negatively impact glaucoma management. Regular monitoring of intraocular pressure and ocular health by an ophthalmologist is essential during treatment. |
Safety & Warnings
Common Side Effects
- Common ocular side effects include ocular burning, stinging, itching, conjunctivitis, blurred vision, superficial punctate keratitis, eye redness, tearing, and dry eyes.
- Some patients may experience blepharitis or eyelid inflammation.
- Systemic absorption of timolol can lead to cardiovascular adverse effects such as bradycardia, hypotension, and exacerbation of cardiac insufficiency or heart block.
- Respiratory effects may include dyspnea, bronchospasm (particularly in patients with pre-existing asthma or COPD), and respiratory failure.
- Other systemic side effects can include headache, dizziness, fatigue, depression, asthenia, nausea, bitter taste, and rarely, alopecia or erectile dysfunction.
- It is crucial for patients to report any unusual or severe symptoms to their healthcare provider promptly.
- Prolonged use may also be associated with corneal edema and other ocular surface changes, necessitating regular ophthalmic examinations.
- Additionally, hypersensitivity reactions, though rare, can occur.
Serious Warnings
- Black Box Warning: Although ophthalmic dorzolamide and timolol does not carry a formal FDA 'Black Box Warning,' it is imperative for healthcare providers and patients to be aware of the significant potential for systemic absorption of the timolol component. This systemic absorption can lead to serious cardiovascular and respiratory adverse reactions, which are well-documented for systemically administered beta-blockers. Of particular concern are individuals with pre-existing conditions such as bronchial asthma, severe chronic obstructive pulmonary disease (COPD), sinus bradycardia, second- or third-degree atrioventricular (AV) block, overt cardiac failure, or cardiogenic shock, as timolol can exacerbate these conditions. Furthermore, beta-adrenergic blocking agents can mask signs and symptoms of acute hypoglycemia in diabetic patients and hyperthyroidism. A thorough medical history, including cardiac, pulmonary, and metabolic assessments, is essential prior to initiation of therapy to mitigate these substantial risks and ensure patient safety.
- Patients receiving dorzolamide and timolol ophthalmic solution should be monitored for potential systemic absorption, which can lead to serious cardiovascular and pulmonary reactions, especially in individuals with pre-existing conditions such as asthma, COPD, or cardiac disease.
- Beta-blockers can mask symptoms of hypoglycemia in diabetic patients and signs of hyperthyroidism, necessitating careful monitoring in these populations.
- Caution is advised in patients with cerebrovascular insufficiency due to potential exacerbation of signs and symptoms.
- The ophthalmic solution contains benzalkonium chloride, which may be absorbed by soft contact lenses; therefore, contact lenses should be removed prior to instillation and reinserted 15 minutes after administration.
- There is a potential for additive effects with concurrent systemic beta-blockers, oral carbonic anhydrase inhibitors, or other topical ophthalmic IOP-lowering medications, increasing the risk of adverse reactions.
- Patients should be advised not to touch the dropper tip to any surface to avoid contamination of the solution and to report any ocular injury or infection immediately.
How it Works (Mechanism of Action)
Dorzolamide and timolol ophthalmic solution combines two distinct mechanisms to lower intraocular pressure (IOP). Dorzolamide is a topical carbonic anhydrase inhibitor that acts on the ciliary body of the eye. It inhibits the enzyme carbonic anhydrase, which is responsible for the formation of bicarbonate ions. This inhibition reduces the active secretion of aqueous humor into the posterior chamber, thereby decreasing its production and consequently lowering IOP. Timolol is a non-selective beta-adrenergic receptor blocker. Its primary mechanism in lowering IOP involves reducing the production of aqueous humor in the ciliary body. While the exact biochemical pathway is not fully elucidated, it is believed to involve the inhibition of beta-2 adrenergic receptors, which are thought to modulate aqueous humor secretion. The combination of these two agents provides an additive or synergistic effect, leading to a more pronounced reduction in IOP than either medication used alone, effectively managing ocular hypertension and open-angle glaucoma.
Commercial Brands (Alternatives)
No other brands found for this formula.